Amgen (AMGN) Earnings Date & Reports

Key Takeaways

• Total revenue rose 10% year over year to $10.1 billion, with product sales up 9% to $9.54 billion.
• Adjusted (non-GAAP) earnings per share came in at $6.29, up 4% from $6.02 a year earlier and above the roughly $5.60 consensus estimate.
• Six key growth drivers grew 26% year over year and now generate nearly 70% of quarterly product sales.
• Repatha, EVENITY, TEZSPIRE, UPLIZNA, and IMDELLTRA all posted double-digit growth, offsetting steep declines in Prolia and XGEVA from biosimilar competition.
• Amgen raised its full-year 2026 revenue and adjusted EPS guidance and generated $3.5 billion in free cash flow.

Earnings Context and Why It Matters

Amgen's second-quarter results arrived at a pivotal moment for the biotech giant. The company is managing a portfolio transition, with older franchises such as Prolia, XGEVA, Otezla, and Enbrel facing biosimilar competition and pricing pressure from the Inflation Reduction Act, while newer medicines in cardiology, oncology, and rare disease carry the growth burden. Investors were watching closely to see whether that newer wave of products could outpace the erosion on legacy brands. The answer, delivered on August 4, 2026, was broadly positive: double-digit volume growth across 22 products lifted the top line past $10 billion and supported a raise in full-year guidance.

Reported Results

Amgen reported total revenue of $10.05 billion for the second quarter of 2026, a 9.5% increase from $9.18 billion in the prior-year period. Product sales rose 8.7% to $9.54 billion, driven primarily by volume growth. The result exceeded the consensus estimate of roughly $9.44 billion.

On a GAAP (Generally Accepted Accounting Principles) basis, earnings per share (EPS) increased 65% to $4.37, up from $2.65 a year ago. On an adjusted, non-GAAP basis, which excludes acquisition-related amortization and other items, EPS rose 4% to $6.29, surpassing the approximately $5.60 consensus estimate. Adjusted operating income climbed 7% to $4.61 billion, and free cash flow, calculated as operating cash flow minus capital expenditures, reached $3.5 billion versus $1.9 billion a year earlier.

Key growth drivers delivered standout performances. Repatha grew 37% to $953 million, EVENITY rose 38% to $714 million, TEZSPIRE gained 42% to $486 million, UPLIZNA jumped 90% to $335 million, and IMDELLTRA surged 115% to $288 million. Meanwhile, Prolia fell 32% to $759 million and XGEVA declined 34% to $352 million as multiple biosimilars launched globally.

Amgen raised its full-year 2026 outlook, now guiding for revenue of $38.2 billion to $39.4 billion and non-GAAP EPS of $22.30 to $23.50, up from prior expectations.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The tool helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings events like Amgen's quarterly results, the AI Screener offers a structured way to identify and compare candidates across sectors.

Market Reaction and Investor Sentiment

The initial market response to Amgen's second-quarter report was measured. Shares traded roughly flat around $389 immediately after the announcement, reflecting results that were strong on headline figures but already anticipated by many investors. The beat on both revenue and adjusted EPS, combined with the upwardly revised guidance, was largely seen as a confirmation of the company's growth narrative rather than a surprise catalyst. Sentiment was further supported by management's emphasis on durable volume growth and the breadth of products delivering double-digit expansion. However, lingering concerns over biosimilar erosion on Prolia and XGEVA, Medicare Part D pricing, and regulatory uncertainty around TAVNEOS tempered enthusiasm, keeping the post-earnings move contained relative to the magnitude of the beat.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Amgen's growth drivers can sustain their momentum through the second half of 2026 and beyond. Management has signaled that biosimilar-related erosion on Prolia and XGEVA could accelerate for the remainder of the year, making the performance of newer medicines critical to maintaining overall top-line growth.

The company's late-stage pipeline will also be a central focus. MariTide, Amgen's investigational obesity treatment, is advancing through multiple Phase 3 trials, while olpasiran for cardiovascular risk and xaluritamig in prostate cancer remain important near-term catalysts. Any clinical or regulatory updates on these programs could move sentiment well before the next earnings report.

Cost and margin dynamics deserve continued attention. Amgen is investing heavily in research and development (R&D) and manufacturing capacity, and management has indicated a sequential increase in operating expenses during the third quarter, including a $100 million upfront payment for a business development transaction. Finally, regulatory matters, including the FDA's request regarding TAVNEOS, add a layer of uncertainty that investors will monitor alongside pricing pressures tied to the Inflation Reduction Act.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations